RECRUITING

Long-term COVID and Rehabilitation

Conditions

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The proposed focuses on improving both morbidity and mortality in older Veterans and those recovering from COVID-19 by developing rehabilitation therapies to augment vascular endothelial function by combating the oxidative stress and inflammation associated with aging and further induced by COVID-19. The investigators expected outcomes will have an important positive impact because they will provide scientifically sound recommendations for rehabilitation to improve vascular endothelial function and minimize the long-term consequences of COVID-19.

Official Title

Evaluating the Long-term Health Consequences of COVID-19 and Rehabilitation Therapies to Speed Convalescence

Quick Facts

Study Start:2022-11-01
Study Completion:2028-10-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05373043

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:Not specified
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * 50 years of age or greater
  2. * Long-COVID and COVID-recovered patients must have SARS-CoV-19 positive test near the time of COVID-19 diagnosis
  3. * Long-COVID and COVID-recovered patients must be 3-12 months post-initial COVID-19 diagnosis
  4. * Ability to sign informed consent
  1. * BMI \>45 kg/m2
  2. * Unstable (\<6 months) or severe coronary artery disease (CAD-RADS score = 4A), peripheral artery disease (Ankle Brachial Index \<0.40), cerebrovascular disease (identified by previous stroke in last 12 months), severe COPD (=Stage III), uncontrolled hypertension (\>160/100 mmHg), chronic kidney disease requiring dialysis, severe renal insufficiency (creatinine clearance \<30 by the Cockcroft-Gault formula), Alzheimer's disease, dementia
  3. * Orthopedic limitations that would prohibit exercise
  4. * \[Current smokers and individuals that stopped smoking in the last 10 years\]
  5. * Already taking Mito-Q or unwilling to cease dietary supplements for participation
  6. * Any other condition or event considered exclusionary by the PIs or a physician

Contacts and Locations

Study Contact

Joel D Trinity, PhD
CONTACT
(801) 582-1565
Joel.Trinity@va.gov
Russell S Richardson, PhD
CONTACT
(801) 582-1565
r.richardson@hsc.utah.edu

Principal Investigator

Joel Douglas Trinity, PhD
PRINCIPAL_INVESTIGATOR
VA Salt Lake City Health Care System, Salt Lake City, UT

Study Locations (Sites)

VA Salt Lake City Health Care System, Salt Lake City, UT
Salt Lake City, Utah, 84148-0001
United States

Collaborators and Investigators

Sponsor: VA Office of Research and Development

  • Joel Douglas Trinity, PhD, PRINCIPAL_INVESTIGATOR, VA Salt Lake City Health Care System, Salt Lake City, UT

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-11-01
Study Completion Date2028-10-31

Study Record Updates

Study Start Date2022-11-01
Study Completion Date2028-10-31

Terms related to this study

Additional Relevant MeSH Terms

  • Long-COVID